ArticleMolecular pharmaceutics2023

Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent.

Raju Subramanian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.